(October 29, 2012) (PRWEB) October 30, 2012 -- The Brain Research Foundation (BRF) today announced that the 2012 recipients of the Frederic A. Gibbs Discovery Award will be Michael W. Ferro Jr. and David M. Holtzman, M.D.
Largest Single Private Investment in Alzheimer’s Whole Genome Sequencing Targets Effective Therapies and Cure: $5.4 Million Awarded for Research to Guide Alzheimer’s Drug Development
Understanding who is most susceptible to Alzheimer’s disease and developing early detection models, effective therapies and possibly a cure, is the goal of the largest single private scientific grant ever invested in Alzheimer’s Whole Genome Sequencing (WGS) focused on families afflicted with the disease.
Cure Alzheimer's Fund is saddened to learn of the death of Senator Arlen Specter. He was a strong supporter of funding for medical and scientific research.
His commitment to medical research and his memory will live on through the Accelerated Cures Network, which he worked tirelessly on and which will help to speed the development of therapies and hopefully cures for many diseases.
October 9 -- Eli Lilly announced encouraging results yesterday involving their experimental drug Solanezumab. Solanezumab is an antibody aimed at lowering beta-amyloid levels in the brain. In trials lasting 18 months, patients with mild Alzheimer's symptoms taking Solanezumab showed significantly less cognitive decline -- 34% less -- compared with patients taking the placebo.
Cure Alzheimer’s Fund Research Consortium member and funded researcher Steven L. Wagner, Ph.D., Principle Investigator, Department of Neurosciences; School of Medicine, and William C. Mobley, M.D., Ph.D., Distinguished Professor and Chair of the Department of Neurosciences, both from the University of California, San Diego, discuss how research into the cause of Alzheimer’s disease brings hope to patients and caregivers, and the role that Cure Alzheimer’s plays in the process.
As a result of Cure Alzheimer’s Fund research, an integrated view of the causes of Alzheimer’s pathology has emerged. That view begins with a concept of what makes up a healthy brain. Abeta, we now know, performs a number of useful functions within the brain. In a healthy brain, moderate amounts of Abeta will be produced and cleared from time to time. Clearance is provided by several proteins, the most important of which are the APOE proteins (of which there are three variants).
A new study by David Holtzman of Cure Alzheimer’s Fund’s Research Consortium published by the journal “Science Translational Medicine” brings sharp new focus on the direct relationship between the accumulation of Abeta in the brain and notorious sleep problems associated with Alzheimer's disease. This NIH-funded study (also supported by Ellison Medical Foundation) was made possible by early pilot studies initiated by the Cure Alzheimer's Fund --- another great example of leveraging innovative research ideas into substantially funded, high impact projects.
After reading Barbara Kingsolver’s Animal Dreams in Honors English at Scituate High School, Lexie Fidas, 15, was given another class assignment—to create a difference in society, much the way the characters in
the book did.
A study just published in the New England Journal of Medicine points to the value of conducting a new series of Alzheimer's prevention studies, suggests Cure Alzheimer's Consortium member Sam Gandy in an accompanying NEJM editorial. The study, led by Washington University's Randall J. Bateman, found that patients with a more genetic-oriented form of Alzheimer's experience a rise in beta-amyloid (Aβ) up to 25 years before symptoms begin -- and an increased level of tau protein up to 15 years before symptoms.
On Friday, August 24, Eli Lilly announced that their beta-amyloid immunotherapy (solanezumab) failed to meet its primary clinical endpoints for Alzheimer's disease. This disappointment follows the recent failure of another promising beta-amyloid immunotherapy, bapineuzumab from Pfizer/Johnson and Johnson-Jannsen/Elan. Both drugs failed in Phase 3 clinical trials, where they were being tested for their actual effect on Alzheimer's patients.
© 2005-2015 Cure Alzheimer's Fund. All rights reserved.